Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Dinaciclib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 18 Dec 2018 Planned number of patients changed from 44 to 48.
- 18 Dec 2018 Planned End Date changed from 2 Jun 2021 to 11 Jun 2021.
- 31 Aug 2018 Biomarkers information updated